Fusen Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Fusen Pharmaceutical's earnings have been declining at an average annual rate of -63.6%, while the Pharmaceuticals industry saw earnings growing at 4.3% annually. Revenues have been growing at an average rate of 5.7% per year.
Key information
-63.6%
Earnings growth rate
-63.6%
EPS growth rate
Pharmaceuticals Industry Growth | 5.6% |
Revenue growth rate | 5.7% |
Return on equity | -17.3% |
Net Margin | -21.1% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
There's Reason For Concern Over Fusen Pharmaceutical Company Limited's (HKG:1652) Price
Dec 18Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
May 21Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 31Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
Dec 14Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly
Sep 02Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly
Apr 02A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns
Mar 06We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide
Feb 08Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 18Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?
Dec 28What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition
Dec 07If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns
Nov 20Revenue & Expenses Breakdown
How Fusen Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 425 | -90 | 188 | 98 |
31 Mar 24 | 496 | -63 | 201 | 82 |
31 Dec 23 | 566 | -36 | 214 | 65 |
30 Sep 23 | 614 | -24 | 227 | 40 |
30 Jun 23 | 663 | -11 | 216 | 39 |
31 Mar 23 | 577 | -23 | 195 | 27 |
31 Dec 22 | 492 | -35 | 173 | 15 |
30 Sep 22 | 414 | -34 | 160 | 8 |
30 Jun 22 | 337 | -34 | 146 | 0 |
31 Mar 22 | 361 | -9 | 151 | 0 |
31 Dec 21 | 386 | 17 | 156 | 0 |
30 Sep 21 | 420 | 48 | 160 | 0 |
30 Jun 21 | 454 | 79 | 165 | 0 |
31 Mar 21 | 470 | 75 | 175 | 0 |
31 Dec 20 | 487 | 70 | 186 | 0 |
30 Sep 20 | 473 | 67 | 190 | 0 |
30 Jun 20 | 458 | 65 | 193 | 0 |
31 Mar 20 | 433 | 59 | 182 | 0 |
31 Dec 19 | 407 | 53 | 172 | 0 |
30 Sep 19 | 397 | 63 | 154 | 0 |
30 Jun 19 | 387 | 72 | 137 | 0 |
31 Mar 19 | 424 | 87 | 138 | 0 |
31 Dec 18 | 462 | 102 | 139 | 0 |
30 Sep 18 | 507 | 102 | 158 | 0 |
30 Jun 18 | 493 | 98 | 156 | 0 |
31 Mar 18 | 473 | 98 | 146 | 0 |
31 Dec 17 | 453 | 97 | 136 | 0 |
30 Sep 17 | 427 | 86 | 127 | 0 |
31 Dec 16 | 442 | 95 | 112 | 0 |
31 Dec 15 | 369 | 45 | 86 | 0 |
Quality Earnings: 1652 is currently unprofitable.
Growing Profit Margin: 1652 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1652 is unprofitable, and losses have increased over the past 5 years at a rate of 63.6% per year.
Accelerating Growth: Unable to compare 1652's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1652 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.4%).
Return on Equity
High ROE: 1652 has a negative Return on Equity (-17.28%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 23:03 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fusen Pharmaceutical Company Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|